42127 Pleasant Forest Court
Ashburn, VA 20148-7349
United States
703 980 4182
https://quoinpharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 4
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Michael Myers Ph.D. | Co-Founder, CEO & Chairman | 661,8k | N/A | 1962 |
Ms. Denise Carter | Co-Founder, COO & Director | 537,8k | N/A | 1969 |
Mr. Gordon Bruce Dunn J.D. | Chief Financial Officer | 394,2k | N/A | 1964 |
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.